Bridgefront Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Bridgefront Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$300K	Buy	+3,778	New	+$284K	0.08%	382
2025 Q2	–	Sell	-20,528	Closed	-$619K	–	725
2025 Q1	$619K	Sell	20,528 -1,274	-6%	-$41.7K	0.18%	195
2024 Q4	$762K	Buy	21,802 +10,606	+95%	+$396K	0.26%	111
2024 Q3	$449K	Buy	11,196 +5,637	+101%	+$262K	0.17%	203
2024 Q2	$265K	Buy	+5,559	New	+$228K	0.11%	333
2023 Q4	–	Sell	-4,948	Closed	-$224K	–	461
2023 Q3	$224K	Buy	+4,948	New	+$204K	0.16%	296
2023 Q2	–	Sell	-7,056	Closed	-$252K	–	564
2023 Q1	$252K	Buy	+7,056	New	+$265K	0.15%	262
2021 Q2	–	Sell	-6,798	Closed	-$306K	–	748
2021 Q1	$306K	Buy	6,798 +1,094	+19%	+$61K	0.1%	421
2020 Q4	$323K	Buy	+5,704	New	+$284K	0.11%	354

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Bridgefront Capital's IONS Position: Q2 2026 in Review

Bridgefront Capital opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 3,778 shares worth $300K. The stake represents 0.08% of the portfolio and ranks #382 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in IONS as recently as Q1 2025.

Bridgefront Capital first reported a position in IONS in Q4 2020 and has held it in 9 quarters since. The position peaked at $762K in Q4 2024. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Bridgefront Capital held 3,778 shares of Ionis Pharmaceuticals worth $300K as of Q2 2026.
Ionis Pharmaceuticals was a new Bridgefront Capital position in Q2 2026.
Ionis Pharmaceuticals made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #382 holding.
Bridgefront Capital first reported a position in Ionis Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
Bridgefront Capital's Ionis Pharmaceuticals position peaked at $762K in Q4 2024.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.